Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100B | P04271 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6199076 | 1.00 | S100B (0.46) | S100BALDH1A1ACHESMN1; SMN2TP53 | |
| SCHEMBL11594058 | 0.85 | KMT2A (0.57) | ALDH1A1TSHRKMT2AMEN1MAPT | |
| SCHEMBL11547155 | 0.80 | CYP2D6 (0.44) | ALDH1A1ACHESMN1; SMN2CA12CA2 | |
| SCHEMBL8595189 | 0.78 | PTGS2 (0.37) | ALDH1A1ACHESMN1; SMN2CA12CA2 | |
| SCHEMBL8585835 | 0.78 | PTGS2 (0.53) | ALDH1A1CA12CA2CA9CA1 | |
| SCHEMBL4361001 | 0.78 | PTGS2 (0.50) | ALDH1A1SMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL14925518 | 0.78 | PTGS2 (0.50) | ALDH1A1SMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL4361000 | 0.78 | PTGS2 (0.50) | ALDH1A1SMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL12534124 | 0.76 | S100B (0.49) | S100BALDH1A1ACHESMN1; SMN2TP53 | |
| SCHEMBL7763844 | 0.76 | S100B (0.49) | S100BALDH1A1ACHESMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948499-B1 | HETEROARYLSULFONAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ABBOTT GMBH & CO KG (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-6353002-B2 | DIOXINOINDOLE AND THIENOBENZODIOXIN COMPOUNDS WHICH ARE HT3 RECEPTOR ANTAGONISTS AND ARE USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | disclosed |
| US-6218405-B1 | THERAPY OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS DEPRESSION, ANXIETY, PSYCHOSES, TARDIVE DYSKINESIA, PARKINSON'S DISEASE, OBESITY, HYPERTENSION, TOURETTE'S SYNDROME, SEXUAL DYSFUNCTION, DRUG ADDICTION, DRUG ABUSE | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-0948499-A1 | HETEROARYLSULFONAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998029415-A1 | HETEROARYLSULFONAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-09 | — | — | WO | disclosed |
| US-4868323-A | FROM N-ARYLFORMIMIDATES AND A LITHIUM DIALKYLAMIDE | MINE SAFETY APPLIANCES COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008903-A1 | Therapeutic agents | GPR119, SNCA, HTR2B | S100B 2266/4885ALDH1A1 3243/4885ACHE 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.